RFG Advisory’s Moderna MRNA Stock Holding History

RFG Advisory’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,128	Closed	-$286K	–	526
2021 Q4	$286K	Buy	1,128 +536	+91%	+$157K	0.02%	407
2021 Q3	$228K	Buy	+592	New	+$218K	0.02%	389

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

RFG Advisory's MRNA Position: Q1 2022 in Review

RFG Advisory sold out of Moderna (MRNA) in Q1 2022, closing a stake of 1,128 shares — an estimated $286K sold.

RFG Advisory first reported a position in MRNA in Q3 2021 and held it in 2 quarters. The position peaked at $286K in Q4 2021. 1,006 funds tracked by Wall St. Rank hold MRNA as of Q1 2022.

RFG Advisory reported no remaining Moderna position as of Q1 2022 after selling out during the quarter.
RFG Advisory sold 1,128 Moderna shares in Q1 2022, an estimated $286K.
RFG Advisory first reported a position in Moderna in Q3 2021 and held it in 2 quarters.
RFG Advisory's Moderna position peaked at $286K in Q4 2021.
1,006 funds tracked by Wall St. Rank held Moderna as of Q1 2022.

Based on RFG Advisory's 13F filing for Q1 2022, filed 11 May 2022.